Key result
Abnormal SPECT linked to ~102% higher MACE risk versus normal SPECT in asymptomatic type 2 diabetes.
Why the study?
The role of screening asymptomatic patients with type 2 diabetes using cardiac imaging remains controversial due to short follow-up in existing studies.
Does abnormal SPECT predict all-cause mortality and MACE in asymptomatic high-risk T2DM patients without a history of CAD?
Cohort (n=400)
Yes
Does abnormal SPECT predict all-cause mortality and MACE in asymptomatic high-risk T2DM patients without a history of CAD?
Hazard Ratio: 2.024
Absolute Event Rate: 2.3% vs 1.2%
p-value: p=0.009
A normal SPECT scan in asymptomatic high-risk T2DM patients is associated with an excellent long-term prognosis, supporting its use for advanced risk stratification.
Supports durable prognostic value of normal SPECT in asymptomatic diabetes; leaves open impact on management or need for randomized trials.
AIMS: Patients with type 2 diabetes mellitus (T2DM) are at high risk for coronary artery disease (CAD) related events and are often asymptomatic. The role of cardiac imaging in screening asymptomatic T2DM patients remains controversial, as existing studies are limited by short follow-up periods. Therefore, study aim was to provide long-term (10 years) outcome data of T2DM patients screened with cardiac imaging. METHODS AND RESULTS: A total of 400 asymptomatic high-risk T2DM patients without history of CAD underwent screening with Single Photon Emission Computed Tomography (SPECT). Abnormal SPECT was defined as Summed Stress Score ≥ 4 or Summed Difference Score ≥ 2. Patients were followed for all-cause mortality and major adverse cardiovascular events (MACE, cardiovascular mortality + myocardial infarction).The mean age was 63 ± 8 years; 69% were male. Diabetic end-organ damage was present in 87% of patients. Baseline SPECT was abnormal in 22% of patients. Median follow-up was 11.1 (8.8, 12.8) years. Abnormal SPECT was associated with higher all-cause mortality [hazard ratio (HR) 1.614, P = 0.029] and MACE (HR 2.024, P = 0.009). A normal SPECT was associated with a significantly better prognosis (all-cause mortality 1.9 vs. 3.1%/year, P = 0.016; MACE 1.2 vs. 2.3%/year, P = 0.010). In the small subgroup of patients with abnormal SPECT, the treatment strategy (revascularization vs. conservative) had no effect on event-free survival. CONCLUSION: A normal SPECT was associated with an excellent long-term prognosis in high-risk T2DM patients. Hence, SPECT could serve as a valuable tool for advanced risk stratification in this population.
No takes yet. Share an insight, caveat, or question.
Thommen et al. (2025) conducted a cohort in Type 2 diabetes mellitus (n=400). Abnormal SPECT vs. Normal SPECT was evaluated on Major adverse cardiovascular events (cardiovascular mortality + myocardial infarction) (HR 2.024, p=0.009). In asymptomatic high-risk patients with type 2 diabetes, an abnormal SPECT was associated with a higher risk of MACE compared to a normal SPECT (2.3 vs. 1.2%/year; HR 2.024, P=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: